Diabetic Peripheral Neuropathy
Conditions
Keywords
focal vibration, wearable, nerve conduction study, pain, mobility
Brief summary
The purpose of this study is to characterize the changes in peripheral nerve functions (sensory and motor) in patients with diabetic peripheral neuropathy, and examine the relations between the changes in nerve functions and changes in pain and mobility using focal vibration.
Detailed description
Peripheral nerve impairments are highly prevalent in patients with diabetic peripheral neuropathy (DPN) and are associated with pain and poor mobility. While peripheral sensorimotor nerve function is implicated in neuropathy, the mechanism associated with both pain and mobility is not well understood. Even less understood is the interplay between, and responses to, sensory and motor fibers of the affected peripheral nerve. In our previous study, focal vibration (FV) was effective in reducing pain and improving mobility for only a subgroup of participants with DPN. Because FV stimulates both motor and sensory peripheral nerve fibers, when combined with nerve conduction testing, it offers a unique opportunity to study both the sensory and motor peripheral nerve performance and their contribution to pain and mobility in patients with DPN. We are proposing a single group, repeated measured study to: characterize the changes in sensory and motor peripheral nerve functions; examine the association(s) between these changes and changes in pain and mobility, using FV. If successful, this study will provide us with a better understanding of the role played by sensory and motor nerve impairments in pain and mobility for DPN, and support larger clinical studies to optimize nerve function performance and the FV parameters. We will also explore how changes in the peripheral nerve function associate with severity of DPN.
Interventions
DEVICEFocal vibration therapy
Myovolt delivers vibration with a frequency between 60-300 Hz, and acceleration force between 1.8g to 19.1g peak to peak. Myovolt intensity will be set to \ up to 2X the participant's initial Myovolt perception threshold (however, the maximum intensity will be limited to 19.1g which is the maximum intensity the device can deliver). If the stimulation does not feel strong, the participant will be asked to manually increase the intensity until it feels strong but comfortable.
Sponsors
University of Oklahoma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A 6-week, single group, repeated measures with double baselines research design to characterize the changes in sensory and motor nerve performance in DPN, and examine the relations between these changes and changes in pain and mobility
Eligibility
Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of diabetes for at least one year; * Diabetic peripheral neuropathy as defined by failure to sense the 5.07 (10g) monofilament test in one or more of the six sites tested; * Age 45-80 years old; * Able to ambulate independently without assistive devices (e.g., walker or crutches) for 30 feet; * No evidence of neurological (other than peripheral neuropathy) or orthopedic conditions; * Able to understand English instructions; * Have normal or corrected vision.
Exclusion criteria
* With other non-diabetic causes of neuropathy by history; * Symptomatic peripheral vascular disease, joint pain, swelling and/or limited range of motion in the lower extremities that interfere with walking; * Other systemic or local diseases that could interfere with walking assessment * Amputation in the lower extremities; * Clinically diagnosed with dementia greater than mild (screened using Montreal Cognitive Assessment (MOCA) \<24)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in CMAP | Change from Baseline CMAP measures every 2 weeks for up to 6 weeks | The peroneal compound muscle action potential (CMAP) |
| Changes in NCV | Change from Baseline NCV measures every 2 weeks for up to 6 weeks | The peroneal motor nerve conduction velocity |
| Changes in SNAP | Change from Baseline SNAP measures every 2 weeks for up to 6 weeks | The digital sensory nerve action potentials |
| Changes in BPI-DPN | Change from Baseline BPI-DPN scores every 2 weeks for up to 6 weeks | The Brief Pain Inventory Short Form for Diabetic Peripheral Neuropathy |
| Changes in TUG | Change from Baseline TUG scores every 2 weeks for up to 6 weeks | Timed Up and Go (TUG) test |
| Changes in NTSS-6 | Change from Baseline NTSS-6 scores every 2 weeks for up to 6 weeks | The Neuropathy Total Symptom Score - 6-items (NTSS-6), which quantifies frequency and intensity of aching, burning, prickling and lancinating pain, numbness, and allodynia in patients' feet and legs. |
| Changes in NSS | Change from Baseline NSS scores every 2 weeks for up to 6 weeks | The Neuropathy Symptom Score (NSS), which quantifies symptoms of motor, sensory, and autonomic deficits. |
| Changes in NIS | Change from Baseline NIS scores every 2 weeks for up to 6 weeks | The Neurologic Impairment Score (NIS), composed of a sensory sub-score (which evaluates sensory perceptions to touch, prickling pain, vibration, joint position, and 1- and 10-g monofilaments in the upper and lower extremities) and a motor sub-score (which evaluates cranial nerves, muscle strength, muscle wasting, and deep tendon reflexes in the upper and lower extremities). |
Countries
United States
Outcome results
None listed